Evidence map›Paper›PMID 40910790›Full record

ReviewHuman vaccines & immunotherapeutics2025

The human papilloma virus (HPV) vaccination recommendations and funded programs for adults: A targeted literature review.

Xuedan You, Miriam Reuschenbach, Astha Jain, Adam Hall, Aastha Jain, Maria Villarejo, Ya-Ting Chen, Nancy Durand

Abstract readReview
In one paragraph

Review in Human vaccines & immunotherapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Xuedan YouDepartment of Outcomes Research, Value and Implementation, Merck & Co., Inc., Rahway, NJ, USA.ORCID 0000-0002-2551-9111
Miriam ReuschenbachDepartment of Global Medical & Scientific Affairs, MSD Sharp & Dohme GmbH, Munich, Germany.
Astha JainEvidence Evaluation, HEOR, Parexel International, Mohali, India.
Adam HallPricing and Market Access, Parexel International, London, UK.
Aastha JainEvidence Evaluation, HEOR, Parexel International, Mohali, India.
Maria VillarejoDepartment of Value & Implementation Global Medical Affairs, MSD Spain, Madrid, Spain.
Ya-Ting ChenDepartment of Outcomes Research, Value and Implementation, Merck & Co., Inc., Rahway, NJ, USA.
Nancy DurandDepartment Obstetrics & Gynaecology, University of Toronto, Toronto, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

HPV vaccination in adults provides opportunities for individuals who were previously ineligible, or who missed vaccination as adolescents, thereby reducing HPV-related disease burden. This targeted literature review summarizes the HPV vaccination recommendations and guidelines by National Immunization Technical Advisory Groups and professional societies, and public funded programs for adults. Of the 152 jurisdictions examined, 62 offered HPV vaccination recommendations for general adults. Of these, 84% included both genders and 68% included sub-populations. Four jurisdictions had recommendations for adult sub-populations only. Overall, 38 jurisdictions had funded programs for general adults and 17 targeted specific sub-populations. The most reported upper eligible age for recommendations or guidelineswas 26 y and 45 y, and 26 y for funded programs. People with HIV and immunosuppressed individuals were the most common sub-populations included. While economic reasons may influence funding for HPV vaccination among adults, clinical guidelines are more likely to advise vaccination on an individual basis, regardless of age.

Indexed as

Immunization ProgramsPapillomavirus InfectionsPapillomavirus VaccinesVaccinationAdultFemaleHuman Papillomavirus VirusesHumansMaleMiddle AgedPractice Guidelines as TopicYoung AdultPapillomavirus Vaccinesadulthealth policyhuman papillomavirus (HPV)Papillomavirus vaccinespractice guidelines as topic, recommendationsvaccination programs

Identifiers

PMID40910790
PMCPMC12416164

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.